Entresto: Novartis loses initial bid to block generic of blockbuster heart drug

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-08-14 06:00 GMT | Update On 2024-08-14 06:00 GMT

London: Novartis, a leading pharmaceutical company, has failed in its attempt to convince a federal court to block MSN Pharmaceuticals, a generic drugmaker, from launching a generic version of Novartis' popular heart-failure medication, Entresto, as per a court decision issued.

U.S. District Judge Richard Andrews in Delaware ruled that Novartis' likelihood of winning its patent infringement lawsuit against MSN Pharmaceuticals was too low to justify a halt to the launch of the generic drug. However, Judge Andrews has temporarily prohibited MSN from selling the drug while Novartis appeals the decision to the U.S. Court of Appeals for the Federal Circuit.

Entresto is Switzerland-based Novartis' best-selling drug, earning the company more than $6 billion in revenue last year. MSN's version of Entresto was approved by the U.S. Food and Drug Administration last month and would be the first U.S. generic of the drug.

According to Reuters, Novartis said in a statement that it was "considering all available options" to defend its intellectual property and "maintains its financial guidance for 2024."

Spokespeople for MSN did not immediately respond to a request for comment on the decision.

Novartis sued MSN and others seeking to launch Entresto generics in 2022 for infringing a patent that expires in 2026. It asked the court on Aug. 2 for a preliminary injunction blocking MSN from launching its generic, which was approved by the FDA on July 24.

Andrews ruled on Monday that Novartis was not likely enough to win on its infringement claims to justify the injunction. The judge also rejected Novartis' argument that a ruling against the company would cause "irreparable harm" by triggering a wave of generic Entresto launches by other drugmakers.

Andrews placed a three-day hold on the case while Novartis appeals to the Federal Circuit.

Novartis has separately asked a Washington, D.C. district court to block MSN's launch as part of a challenge to the FDA's decision to approve the generic. The Washington court has not yet ruled on Novartis' request.

Article Source : with inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Entresto: Novartis loses initial bid to block generic of blockbuster heart drug

Similar News